Palomar Medical Technologies Inc  

(Public, NASDAQ:PMTI)   Watch this stock  
Find more results for PMTI
13.44
-0.13 (-0.96%)
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.40 - 13.59
52 week 7.06 - 13.97
Open 13.56
Vol / Avg. 114,436.00/145,947.00
Mkt cap 268.45M
P/E     -
Div/yield     -
EPS -0.27
Shares 19.97M
Beta 1.42
Inst. own 62%
Jul 22, 2013
Q2 2013 Palomar Medical Technologies Inc Earnings Release Add to calendar
Jun 24, 2013
Palomar Medical Technologies Inc Extraordinary Shareholder Meeting Add to calendar
May 2, 2013
Q1 2013 Palomar Medical Technologies Inc Earnings Conference Call
May 2, 2013
Q1 2013 Palomar Medical Technologies Inc Earnings Release
Mar 18, 2013
Cynosure Inc. Signs Definitive Agreement to Acquire Palomar Medical Technologies - Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -4.79% -7.66%
Operating margin -4.04% -7.44%
EBITD margin - -5.61%
Return on average assets -2.63% -3.56%
Return on average equity -2.96% -4.04%
Employees 250 -
Carbon Disclosure Rating - -

Address

15 Network Drive
BURLINGTON, MA 1803
United States - Map
+1-781-9932300 (Phone)
+1-781-9932330 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Palomar Medical Technologies, Inc. (Palomar) is a researcher and developer of aesthetic light-based systems for hair removal and other cosmetic procedures, including both lasers and high powered lamps. The Company offers a range of products based on technologies that include, but are not limited to: hair removal; body sculpting, including laser-assisted liposuction; removal of vascular lesions, such as rosacea, spider veins, port wine stains and hemangiomas; wrinkle reduction; removal of leg veins; removal of benign pigmented lesions, such as age and sun spots, freckles and melasma; tattoo removal; acne treatment; skin resurfacing, pseudofolliculitis barbae (PFB) treatment; treatment of red pigmentation in hypertrophic and keloid scars; treatment of verrucae, skin tags and seborrheic keratosis; skin tightening through soft tissue coagulation; scars, including acne scars, stretch marks and warts, soft tissue coagulation and other skin treatments.

Officers and directors

Joseph P. Caruso Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Paul S. Weiner Chief Financial Officer, Treasurer
Portrait. Age: 48
Bio & Compensation  - Reuters
Louis P. Valente Director
Portrait. Age: 81
Bio & Compensation  - Reuters
Jeanne Cohane Independent Director
Age: 65
Bio & Compensation  - Reuters
Damian N. Dell'Anno Independent Director
Age: 52
Bio & Compensation  - Reuters
Nicholas P. Economou Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
James G. Martin Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters